Fig. 2: CTCAE as predictor of disease severity and clinical course.
From: Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
a Duration of steroids by CTCAE grade of diarrhoea shows difference between G1 and higher (G1 median 27 days, G2 64 days, G3 64 days, G4 73 days) (Kruskal−Wallis G1 vs. rest: p = 0.002) but no difference between other grades (Kruskal−Wallis: p = 0.92) (N.B. Treatment duration data not available for 15% (20) of patients). b Requirement for infliximab by CTCAE grade of diarrhoea shows no difference (chi-squared test: p = 0.18). c Proportion of patients by CTCAE grade of diarrhoea. d Requirement for infliximab by CTCAE grade of colitis shows patients with grade 3/4 colitis were more likely to be treated with infliximab than those with grade 1/2 (Fisher’s exact: p < 0.0001). e Duration of steroids by CTCAE grade of colitis shows difference between G1 and higher (G1 median 22 days, G2 58 days, G3 85 days, G4 65 days) (Kruskal−Wallis G1 vs. rest: p = 0.002) but no difference between other grades (Kruskal−Wallis: p = 0.23). f Proportion of patients by CTCAE grade of colitis.
